Work

1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial

Year: 2022

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.1491

Authors: M. Parry, E. Grist, C. Brawley, J.A. Proudfoot, L. Mendes, S. Lall, A.P. Hoyle, A. Sachdeva, Y. Liu, C. Amos, M.R. Sydes, R. Jones, M.K. Parmar, F. Feng, C.J. Sweeney, N. Clarke, E. Davicioni, N.D. James, L. Brown, G. Attard

Institutions: University College London, Medical Research Council, Veracyte (United States), The Christie Hospital, The Christie NHS Foundation Trust, Cancer Research UK, MRC Clinical Trials Unit at UCL, University of Glasgow, MBC BioLabs (United States), Dana-Farber Cancer Institute, University of Manchester, Institute of Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Prostate Cancer Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Exelixis, Clovis Oncology, Veracyte, Cancer Research UK, University College London, Prostate Cancer UK, Astellas Pharma, Ipsen, Genentech, Foundation Medicine, Medical Research Council, Janssen Pharmaceuticals

OpenAlex ID: W4295828563

FWCI: 0.65

Cites:

Cited by: 4

Related to: 10